REXAHN PHARMACEUTICALS, INC. Human Resources Contracts & Agreements
53 Contracts & Agreements
- Bonus & Incentive Agreements (6 contracts)
- Compensation Agreements (4)
- Consulting Agreements (10)
- Employment Agreements (30)
- Separation Agreements (3)
- Consulting Agreement, dated as of October 22, 2024, by and between the Company and Dr. Jean Bennett (Filed With SEC on November 12, 2024)
- Employment Agreement, dated as of October 22, 2024, by and between the Company and Dr. Benjamin Yerxa (Filed With SEC on November 12, 2024)
- Third Amended and Restated Non-Employee Director Compensation Plan, dated as of June 11, 2024 (Filed With SEC on August 13, 2024)
- Third Amendment to the Consulting Agreement, dated as of January 1, 2024, by and between the Company and Jay Pepose, M.D (Filed With SEC on May 10, 2024)
- Consulting Agreement between Ocuphire Pharma, Inc. and Jay Pepose, M.D., dated April 11, 2024 (Filed With SEC on April 17, 2024)
- First Amendment to Employment Agreement, entered into on February 16, 2024, by and between the Company and Nirav Jhaveri (Filed With SEC on February 16, 2024)
- Employment Agreement, dated February 13, 2024, by and between the Company and Nirav Jhaveri (Filed With SEC on February 16, 2024)
- First Amendment to Amended and Restated Employment Agreement, dated as of December 1, 2023, by and between Ocuphire Pharma, Inc. and Ronil Patel (Filed With SEC on December 6, 2023)
- Amended and Restated Employment Agreement, dated as of April 24, 2023, by and between Ocuphire Pharma, Inc. and Ronil Patel (Filed With SEC on December 6, 2023)
- Employment Agreement entered into on October 31, 2023 by and between Ocuphire Pharma, Inc. and George Magrath (Filed With SEC on November 1, 2023)
- Separation and Release Agreement by and between Ocuphire Pharma, Inc. and Mina Sooch, dated June 8, 2023 (Filed With SEC on August 11, 2023)
- Non-Employee Director Compensation Policy (Filed With SEC on May 15, 2023)
- Interim President and CEO Consulting Letter Agreement by and between Ocuphire Pharma, Inc. and Richard Rodgers, dated April 20, 2023 (Filed With SEC on May 15, 2023)
- Second Amendment to the Consulting Agreement dated December 1, 2022, by and between the Company and Jay Pepose (Filed With SEC on March 30, 2023)
- First Amendment to the Consulting Agreement dated September 19, 2022, by and between the Company and Jay Pepose (Filed With SEC on March 30, 2023)
- First Amendment to the Employment Agreement by and among the Company and Amy Rabourn, effective as of March 26, 2023 (Filed With SEC on March 30, 2023)
- Form of Stock Option Grant Notice issued under the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 30, 2023)
- Form of Restricted Stock Unit Grant Notice issued under the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 30, 2023)
- First Amendment to the Amended and Restated Employment Agreement by and among the Company and Bernhard Hoffmann, effective as of March 26, 2023 (Filed With SEC on March 30, 2023)
- First Amendment to the Amended and Restated Employment Agreement by and among the Company and Mina Sooch, effective as of March 26, 2023 (Filed With SEC on March 30, 2023)
- Non-Employee Director Compensation Policy (Filed With SEC on August 12, 2022)
- Consulting Agreement between the Registrant and Jay Pepose dated April 8, 2022 (Filed With SEC on May 13, 2022)
- Employment Agreement dated November 11, 2020, by and between the Company and Amy Rabourn (Filed With SEC on March 11, 2021)
- Non-Employee Director Compensation Policy of the Company (Filed With SEC on November 6, 2020)
- Form of Option Agreement issuable under the Ocuphire Pharma, Inc. 2018 Equity Incentive Plan (Filed With SEC on July 6, 2020)
- First Amendment to 2018 Equity Incentive Plan, dated as of December 23, 2019 (Filed With SEC on July 6, 2020)
- Ocuphire Pharma, Inc. 2018 Equity Incentive Plan, dated as of April 9, 2019 (Filed With SEC on July 6, 2020)
- Amended and Restated Employment Agreement by and among Ocuphire Pharma, Inc. and Bernhard Hoffmann, to be effective as of the Closing (Filed With SEC on July 6, 2020)
- Employment Agreement, dated as of October 1, 2018, between Ocuphire Pharma, Inc. and Bernhard Hoffmann (Filed With SEC on July 6, 2020)
- Amended and Restated Employment Agreement by and among Ocuphire Pharma, Inc. and Mina Sooch, to be effective as of the Closing (Filed With SEC on July 6, 2020)
- Employment Agreement, dated as of October 1, 2018, between Ocuphire Pharma, Inc. and Mina Sooch (Filed With SEC on July 6, 2020)
- Separation, Transition and General Release Agreement dated November 14, 2018 (Filed With SEC on November 16, 2018)
- Amendment to Employment Agreement dated November 14, 2018 (Filed With SEC on November 16, 2018)
- Separation, Transition and General Release Agreement, dated as of December 11, 2017, by and between Rexahn Pharmaceuticals, Inc. and Tae Heum (Ted) Jeong (Filed With SEC on March 9, 2018)
- Employment Agreement by and between Rexahn Pharmaceuticals, Inc. and Douglas Swirsky effective January 2, 2018 (Filed With SEC on January 4, 2018)
- Employment Agreement dated July 6, 2016 by and between Rexahn Pharmaceuticals, Inc. and Lisa Nolan, Ph.D (Filed With SEC on November 4, 2016)
- Bonus Letter Agreement, dated August 2, 2016, by and between Rexahn Pharmaceuticals, Inc. and Ely Benaim, M.D (Filed With SEC on August 5, 2016)
- Employment Agreement dated as of February 2, 2015, by and between Rexahn Pharmaceuticals, Inc. and Ely Benaim, M.D (Filed With SEC on May 8, 2015)
- Employment Agreement by and between Rexahn Pharmaceuticals, Inc. and Dr. Chang H. Ahn, dated as of March 25, 2013 (Filed With SEC on March 29, 2013)
- EMPLOYMENT AGREEMENT (Filed With SEC on January 22, 2013)
